Optimal treatment for children with haemophilia: a review@@@Optimalus hemofilija sergančių vaikų gydymas (apžvalga)

correspondence to: Sonata Šaulytė trakymienė, Faculty of medicine, Vilnius university, Santariškių 7, lt-08661 Vilnius, lithuania. e-mail: sonata.trakymiene@vuvl.lt Background. Haemophilia is a rare, sex-linked inherited disorder caused by deficiencies of coagulation factor VIII or IX. The hallmark of severe haemophilia is recurrent bleedings into joints, resulting in lasting and irreversible changes and leading to haemophilic arthropathy. Treatment of haemophiliacs has undergone a revolutionary development. Prevention of joint bleed and haemophiliac arthropathy is possible by early regular administration of the deficient clotting factor, defined as prophylactic treatment. The purpose of this paper is to review the current knowledge of prophylactic treatment in haemophilia and the related aspects, and to discuss haemophilia care development and capabilities in Lithuania. Materials and methods. The literature data for the period 1992–2008 concerning prophylactic treatment from historical to current knowledge and haemophilia care development in Lithuania were analysed. Results. Data from observational studies and a recent randomized trial have shown that early prophylaxis is superior to on-demand treatment to prevent joint bleeds and arthropathy development. Despite quite a long experience with prophylactic treatment in some countries and the fact that it is recommended by international authorities, opinions concerning the prophylaxis differ in the world, and there is no uniform clinical practice because of lots of barriers. On-demand treatment strategy with plasma-derived factor concentrates is the standard practice in most clinics of Lithuania. Conclusions. The importance of prophylaxis is unquestioned today. Although definitive recommendations concerning one uniform prophylactic regimen cannot be made so far, primary prophylaxis nowadays is considered to be a standard care of children with severe haemophilia. In Lithuania, haemophilia still causes a significant morbidity because of its suboptimal treatment.

[1]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[2]  G. Auerswald,et al.  Haemophilia care in children – benefits of early prophylaxis for inhibitor prevention , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  P. Mannucci,et al.  Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters , 2008, British journal of haematology.

[4]  R. Ljung,et al.  Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG) , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  M. Bullinger,et al.  Lebensqualität von jungen Patienten mit Hämophilie in Europa , 2008, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[6]  T. Spector,et al.  Individuals with a genetic shift in haematological indices , 2008 .

[7]  M. Bullinger,et al.  [Quality of life of young patients with haemophilia in Europe]. , 2008, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

[8]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[9]  V. Blanchette,et al.  Definitions for haemophilia prophylaxis and its outcomes: The Canadian Consensus Study , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  B. Feldman,et al.  Hemophilia joint health score reliability study , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  V. Blanchette,et al.  Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  A. Abad,et al.  Recent developments in clinimetric instruments , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  P. Babyn,et al.  Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.

[14]  P. Bolton-Maggs,et al.  Optimal haemophilia care versus the reality , 2006, British journal of haematology.

[15]  S. Donadel-Claeyssens Current co‐ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management) , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  K. Fischer,et al.  Can long‐term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands , 2005, British journal of haematology.

[17]  R. Ljung,et al.  Changing pattern of care of boys with haemophilia in western European centres , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  P. Babyn,et al.  Proceedings of the International Haemophilia Prophylaxis Study Group Meeting, November 2003, Montreal, PQ, Canada , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  H. Chambost,et al.  Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  R. Ljung,et al.  Optimizing factor prophylaxis for the haemophilia population: where do we stand? , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  E. Remor,et al.  Disease‐specific quality‐of‐life measurement tools for haemophilia patients , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  L. Valentino,et al.  Central venous access devices in haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  M. Bullinger,et al.  Quality of life assessment in haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  M. Bullinger,et al.  Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo‐QoL) , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  M. Bullinger,et al.  Quality of Life in Children and Families With Bleeding Disorders , 2003, Journal of pediatric hematology/oncology.

[26]  M. Manco‐Johnson Update on treatment regimens: prophylaxis versus on-demand therapy. , 2003, Seminars in hematology.

[27]  V. Blanchette,et al.  A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  E. Rodríguez‐Merchán Orthopaedic assessment in haemophilia , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[29]  P. Petrini How to start prophylaxis , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  A. Shapiro A global view on prophylaxis: possibilities and consequences , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  R. Nuss,et al.  Radiological assessment of haemophilic arthropathy with emphasis on MRI findings , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  J. Astermark,et al.  Consensus perspectives on prophylactic therapy for haemophilia: summary statement , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  K. Fischer,et al.  Prophylaxis for Severe Hemophilia: Experience from Europe and the United States , 2003, Seminars in thrombosis and hemostasis.

[34]  R. Ljung Third and Fourth Workshops of the European paediatric network for haemophilia management , 2003 .

[35]  D. Grobbee,et al.  Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[36]  D. Grobbee,et al.  Prophylactic treatment for severe haemophilia: comparison of an intermediate‐dose to a high‐dose regimen , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[37]  D. Grobbee,et al.  The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. , 2002, Blood.

[38]  K. Fischer,et al.  Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[39]  M. Bullinger,et al.  Pilot testing of the ‘Haemo‐QoL’ quality of life questionnaire for haemophiliac children in six European countries , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  R. Ljung Aspects of haemophilia prophylaxis in Sweden , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[41]  P. Giangrande,et al.  Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[42]  P. Miller Central venous access devices , 2006, Bone Marrow Transplantation.

[43]  D. Grobbee,et al.  Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[44]  C. Müller,et al.  Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data , 2001, British journal of haematology.

[45]  F. Beek,et al.  Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia , 2001, British journal of haematology.

[46]  P. Petrini What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[47]  M. Siimes,et al.  Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[48]  M. Manco‐Johnson,et al.  Joint evaluation instruments for children and adults with haemophilia , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[49]  Sultan,et al.  Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[50]  H. Jürgens,et al.  When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study , 1999, European journal of pediatrics.

[51]  Ljung Second Workshop of the European Paediatric Network for Haemophilia Management, 17–19 September 1998 in Vitznau/Switzerland , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[52]  J. Astermark,et al.  Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized , 1999, British journal of haematology.

[53]  R. Ljung,et al.  Port‐A‐Cath usage in children with haemophilia: experience of 53 cases , 1998, Acta paediatrica.

[54]  C. Kessler,et al.  When should prophylactic treatment in patients with haemophilia A and B start?— The German experience , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[55]  J. Sanders,et al.  Implantable venous access devices in children with hemophilia: a report of low infection rates. , 1998, The Journal of pediatrics.

[56]  Jurgutis,et al.  The Malmö–Klaipeda WFH twinning programme: a comparative description of the Haemophilia cohorts , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[57]  V. Blanchette,et al.  Central venous access devices in children with hemophilia: an update. , 1997, Blood Coagulation and Fibrinolysis.

[58]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[59]  K. Khair,et al.  The impact of prophylactic treatment on children with severe haemophilia , 1996, British journal of haematology.

[60]  E. Rodríguez‐Merchán Effects of hemophilia on articulations of children and adults. , 1996, Clinical orthopaedics and related research.

[61]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[62]  M. Manco‐Johnson,et al.  Results of secondary prophylaxis in children with severe hemophilia , 1994, American journal of hematology.

[63]  W. Schramm Experience with prophylaxis in Germany. , 1993, Seminars in hematology.

[64]  M. Gilbert Prophylaxis: musculoskeletal evaluation. , 1993, Seminars in hematology.

[65]  R. Ljung,et al.  Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia , 1992, Acta paediatrica.

[66]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[67]  H. Pettersson,et al.  RADIOLOGIC EVALUATION OF PROPHYLAXIS IN SEVERE HAEMOPHILIA , 1981, Acta paediatrica Scandinavica.

[68]  Å. Ahlberg,et al.  HAEMOPHILIA PROPHYLAXIS IN SWEDEN , 1976, Acta paediatrica Scandinavica.

[69]  Eric F. Gardner,et al.  Summary Statement , 1946 .